Close Menu
The Startup StoryThe Startup Story
  • Business
  • Lifestyle
  • National
  • Education
  • Health
  • Technology
  • World

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

Ye Mahaveer Ka Panth Hai, Har Prani Me Sant Hai’ – Mahavir Nirvana Katha resonates at Bharat Mandapam

November 16, 2026

Unihealth Hospitals Limited Reports H1 FY27 Revenue of Rs 76.45 Crore; Positive Operating Cash Flow of Rs 23.83 Crore Amidst Significant Expansion Investments

November 16, 2026

Chhattisgarh CM Inaugurates PanIIT Alumni India’s Nursing Skill College Initiative in Jashpur

November 16, 2026
Facebook X (Twitter) Instagram
Trending
  • Ye Mahaveer Ka Panth Hai, Har Prani Me Sant Hai’ – Mahavir Nirvana Katha resonates at Bharat Mandapam
  • Unihealth Hospitals Limited Reports H1 FY27 Revenue of Rs 76.45 Crore; Positive Operating Cash Flow of Rs 23.83 Crore Amidst Significant Expansion Investments
  • Chhattisgarh CM Inaugurates PanIIT Alumni India’s Nursing Skill College Initiative in Jashpur
  • 8th International HKL Conference Begins at Gurdwara Bulandpuri Sahib; Flags of 116 Nations Hoisted to Promote Global Unity
  • Cash Ur Drive Marketing Reports Strong H1 FY27 Performance: EBITDA Rising 13% and Net Profit Growing 8% YoY
  • Shyam Dhani Industries Limited Reports H1 FY27 Financial Performance
  • Apollo Health strengthens its expansion in North India with New Clinic and National Reference Laboratory in Gurugram
  • Batman x Samsonite: Iconic DC Super Hero, Reimagined Through the Lens of Modern Travel
The Startup StoryThe Startup Story
  • Business
  • Lifestyle
  • National
  • Education
  • Health
  • Technology
  • World
The Startup StoryThe Startup Story
Home»National»TB Alliance committed to accessibility of TB therapy in India
National

TB Alliance committed to accessibility of TB therapy in India

By March 24, 2022No Comments
Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email
Read Time:3 Minute, 18 Second

The DCGI (Drug Controller General of India) approved TB drug, pretomanid, for conditional access under the National Tuberculosis Elimination Program (NTEP), can play a significant role towards elimination of highly drug-resistant TB in India 

Pretomanid is a ‘made in India’ product used as part of a six-month treatment regimen with reported efficacy of 90%; has potential to contribute to India’s ‘TB Elimination program by 2025’ 

New Delhi, India March 24: The world continues to battle against pandemics, including COVID-19 and tuberculosis (TB). March 24, marks World TB Day and TB Alliance, a global not-for-profit organization, is joining with partners around the globe to raise awareness of one of the world’s oldest diseases. TB had been the world’s leading infectious killeruntil COVID-19. This new pandemic has shown that new tools, diagnostics, drugs, and vaccines can be quickly developed and deployed with the adequate funding and political will. The same resources are needed to bring the TB pandemic under control and make progress toward a TB-free world.

In July 2020, the Drug Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.

On the occasion of World TB Day, Sandeep Juneja, Sr. VP, Market Access at TB Alliance, said“New regimens are urgently needed to treat this deadly infectious disease, especially drug-resistant forms of TB which have a history of poor cure rates and treatments with often intolerable side effects. We welcome the fact that more than 30 countries, including India, have obtained pretomanid-based regimens to treat highly drug-resistant forms of TB.TB Alliancestands ready to work side by side and learn from India and every other country seeking to implementnew TB therapies. Our job is not done until each treatment we develop is accessible to every person who needs it.”

A government-led study of the regimen in India called *mBPaL commenced in October 2021 and is now enrolling patients at three sites out of a planned 11. It is scheduled to reach its primary completion in 2023 after enrolling 400 patients.

TB Alliance manages the largest portfolio of TB drug candidates, with more than 30 projects under active development. Its researchers and research partners are working to advance the development of new TB compounds and medicines, with a goal to develop a short, simple, and affordable TB regimens suitable for all people with TB.

To date, 17 countries or regulatory bodies, including India, have approved pretomanid as part of the BPaL regimen for the treatment of patients with highly drug-resistant forms of TB. Regulatory applications have been submitted to another 13 countries and counting by Viatris, TB Alliance’s global commercialization partner for pretomanid as part of the regimen. Viatris is joined by Macleods, Lupin, and Hongqi Pharma in holding licenses for pretomanid in countries with high TB burdens.

Data from TB Alliance’s ZeNix trial of the BPaL regimen, presented in 2021, demonstrated improvement in the safety and tolerability of the BPaL regimen with alterations in linezolid dosing with sustained favorable outcomes in 89 precent of all participants.

Though important advances have been made in recent years, the need to invest in TB research and development is even more apparent amidst the COVID-19 pandemic, which has already reversed hard-won progress against TB. In 2020, the world saw the first increase in TB deaths since 2005, and a 15 percent reduction in the number of people treated for drug-resistant TB.

Bringing the TB pandemic under control can only be realized through global commitment and collaboration. TB Alliance is committed to contributing to this aspiration by inventing novel therapies that radically reshape the treatment landscape and save lives.

*BPaL regimen combines the antibiotics bedaquiline (B), pretomanid (Pa) and linezolid (L)

About Post Author


RNT Reporter


dhaval.rntoday@gmail.com

https://republicnewstoday.com

national
Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email

Related Posts

World Diabetes Day: Making Smarter Snacking Choices with American Pistachios

November 16, 2026

SOUHARDYA 2026 Inaugurated at RGIPT Jais, Promoting Social Innovation, Sustainability and Entrepreneurship

November 2, 2026

India’s CNAP caller-name display goes live on 4G and 5G networks from November 1

October 31, 2026

Comments are closed.

Top Posts

Can we guess, how much she is happy?

February 22, 2020

When sunrise and the day begins.

February 22, 2020

Make your own inhouse library and learn

February 22, 2020

Final Battle – Avengers: Infinity War – Youtube

February 22, 2020
Don't Miss
Lifestyle

Ye Mahaveer Ka Panth Hai, Har Prani Me Sant Hai’ – Mahavir Nirvana Katha resonates at Bharat Mandapam

By Arjun SinghNovember 16, 2026

Musical Katha by Rajiv Jain CA brings alive saga of Pawapuri, message of Ahimsa from…

Unihealth Hospitals Limited Reports H1 FY27 Revenue of Rs 76.45 Crore; Positive Operating Cash Flow of Rs 23.83 Crore Amidst Significant Expansion Investments

November 16, 2026

Chhattisgarh CM Inaugurates PanIIT Alumni India’s Nursing Skill College Initiative in Jashpur

November 16, 2026

8th International HKL Conference Begins at Gurdwara Bulandpuri Sahib; Flags of 116 Nations Hoisted to Promote Global Unity

November 16, 2026
Most Popular

Can we guess, how much she is happy?

February 22, 2020

When sunrise and the day begins.

February 22, 2020

Make your own inhouse library and learn

February 22, 2020
Categories
  • Business
  • Business News
  • Education
  • Entertainment
  • Finance
  • Health
  • Lifestyle
  • National
  • Press Release
  • Sports
  • Technology
  • Uncategorized
  • World
Our Picks

Ye Mahaveer Ka Panth Hai, Har Prani Me Sant Hai’ – Mahavir Nirvana Katha resonates at Bharat Mandapam

November 16, 2026

Unihealth Hospitals Limited Reports H1 FY27 Revenue of Rs 76.45 Crore; Positive Operating Cash Flow of Rs 23.83 Crore Amidst Significant Expansion Investments

November 16, 2026

Chhattisgarh CM Inaugurates PanIIT Alumni India’s Nursing Skill College Initiative in Jashpur

November 16, 2026

Type above and press Enter to search. Press Esc to cancel.